HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
BCKDHB
branched chain keto acid dehydrogenase E1 subunit beta
Chromosome 6 · 6q14.1
NCBI Gene: 594Ensembl: ENSG00000083123.16HGNC: HGNC:987UniProt: A0A140VKB3
75PubMed Papers
21Diseases
0Drugs
226Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
branched-chain 2-oxo acid dehydrogenase activityprotein bindingbranched-chain alpha-keto acid decarboxylation to branched-chain acyl-CoAmitochondrionmaple syrup urine disease type 1Bmaple syrup urine diseasemaple syrup urine disease type 1Agenetic disorder
✦AI Summary

BCKDHB encodes the E1β subunit of the branched-chain α-ketoacid dehydrogenase (BCKD) complex, a mitochondrial multienzyme that catalyzes the first committed step in branched-chain amino acid (BCAA) metabolism 1. BCKDHB forms a heterotetrameric E1 complex with BCKDHA, initiating oxidative decarboxylation of α-ketoacids derived from valine, leucine, and isoleucine, ultimately generating acyl-CoA for energy production 1. The decarboxylation involves lipoylamide cofactor-mediated reductive acylation by the E2 subunit, extracting the acyl group for subsequent catalytic steps 1. Biallelic BCKDHB mutations cause maple syrup urine disease type 1B (MSUD-1B), a severe inborn error of metabolism characterized by life-threatening neurologic crises and progressive brain injury resulting from toxic accumulation of branched-chain amino acids and 2-ketoacids 12. Currently managed only through strict protein-restricted diets or liver transplantation, MSUD-1B presents significant clinical burden 1. Beyond MSUD, BCKDHB expression is post-transcriptionally regulated in cardiac tissue, where proper BCAA metabolism is essential for maintaining mitochondrial function and preventing heart failure 3. Dysregulation of BCKDHB contributes to impaired BCAA homeostasis in diabetic cardiomyopathy and sevoflurane-induced neuronal injury 45. Gene replacement therapy using dual-function AAV vectors successfully restores BCKDHB expression and metabolic function in mouse models, representing a promising therapeutic alternative 16.

Sources cited
1
BCKDHB forms heterotetrameric E1 complex with BCKDHA catalyzing oxidative decarboxylation of branched-chain α-ketoacids; mutations cause MSUD-1B; gene therapy restoration prevents disease in animal models
PMID: 40009698
2
BCKDHB mRNA stability is post-transcriptionally regulated by GRSF1; BCKDHB maintains cardiac BCAA homeostasis and mitochondrial function; BCKDHB deletion impairs cardiac function
PMID: 41487100
3
Biallelic BCKDHB mutations cause classical MSUD in neonates; clinical presentation includes poor feeding, seizures, and respiratory failure
PMID: 34187135
4
BCKDHB is aberrantly regulated in diabetic cardiomyopathy contributing to disordered BCAA metabolism; KLF15 regulates BCKDHB expression
PMID: 39623870
5
AAV8-mediated BCKDHB gene therapy achieves long-term rescue of severe MSUD phenotype in Bckdhb-/- mice
PMID: 36880392
6
BCKDHB expression is upregulated in sevoflurane-treated rat hippocampus; BCKDHB knockdown protects hippocampal neurons from sevoflurane-induced apoptosis
PMID: 36813076
7
BCKDHB gene localizes to chromosome 6p21-22
PMID: 1889817
Disease Associationsⓘ21
maple syrup urine disease type 1BOpen Targets
0.79Strong
maple syrup urine diseaseOpen Targets
0.75Strong
maple syrup urine disease type 1AOpen Targets
0.71Strong
genetic disorderOpen Targets
0.49Moderate
Abnormality of the skeletal systemOpen Targets
0.41Moderate
classic maple syrup urine diseaseOpen Targets
0.37Weak
intermediate maple syrup urine diseaseOpen Targets
0.37Weak
intermittent maple syrup urine diseaseOpen Targets
0.37Weak
Abnormality of metabolism/homeostasisOpen Targets
0.34Weak
placenta praeviaOpen Targets
0.32Weak
liver diseaseOpen Targets
0.31Weak
Hallux valgusOpen Targets
0.30Weak
severe acute respiratory syndromeOpen Targets
0.29Weak
type 2 diabetes mellitusOpen Targets
0.29Weak
non-alcoholic fatty liver diseaseOpen Targets
0.29Weak
COVID-19Open Targets
0.28Weak
frozen shoulderOpen Targets
0.27Weak
ovarian dysfunctionOpen Targets
0.27Weak
neurodegenerative diseaseOpen Targets
0.25Weak
ventral herniaOpen Targets
0.21Weak
Maple syrup urine disease 1BUniProt
Pathogenic Variants226
NM_183050.4(BCKDHB):c.152del (p.Val51fs)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2026→ Residue 51
NM_183050.4(BCKDHB):c.832G>A (p.Gly278Ser)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|not provided|Maple syrup urine disease type 1A|BCKDHB-related disorder
★★☆☆2026→ Residue 278
NM_183050.4(BCKDHB):c.548G>C (p.Arg183Pro)Pathogenic
Maple syrup urine disease|not provided|Maple syrup urine disease type 1B|Inborn genetic diseases|Maple syrup urine disease type 1A
★★☆☆2026→ Residue 183
NM_183050.4(BCKDHB):c.547C>T (p.Arg183Trp)Pathogenic
not provided|Maple syrup urine disease type 1B|Maple syrup urine disease
★★☆☆2026→ Residue 183
NM_183050.4(BCKDHB):c.580C>T (p.Leu194Phe)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B
★★☆☆2026→ Residue 194
NM_183050.4(BCKDHB):c.595_596del (p.Ser199_Pro200insTer)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|not provided|Maple syrup urine disease type 1A
★★☆☆2026→ Residue 199
NM_183050.4(BCKDHB):c.348del (p.Asp117fs)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|Maple syrup urine disease type 1A
★★☆☆2026→ Residue 117
NM_183050.4(BCKDHB):c.509G>A (p.Arg170His)Pathogenic
not provided|Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2026→ Residue 170
NM_183050.4(BCKDHB):c.641T>A (p.Ile214Lys)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2026→ Residue 214
NM_183050.4(BCKDHB):c.799C>T (p.Gln267Ter)Pathogenic
Maple syrup urine disease|not provided|Maple syrup urine disease type 1B|Maple syrup urine disease type 1A
★★☆☆2026→ Residue 267
NM_183050.4(BCKDHB):c.970C>T (p.Arg324Ter)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|not provided|Maple syrup urine disease type 1A
★★☆☆2025→ Residue 324
NM_183050.4(BCKDHB):c.633+1G>APathogenic
not provided|Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2025
NM_183050.4(BCKDHB):c.1006G>A (p.Gly336Ser)Pathogenic
not provided|Maple syrup urine disease type 1B|Maple syrup urine disease|Maple syrup urine disease type 1A
★★☆☆2025→ Residue 336
NM_183050.4(BCKDHB):c.1A>G (p.Met1Val)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|Maple syrup urine disease type 1A
★★☆☆2025→ Residue 1
NM_183050.4(BCKDHB):c.1016C>T (p.Ser339Leu)Pathogenic
not provided|Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2025→ Residue 339
NM_183050.4(BCKDHB):c.1A>T (p.Met1Leu)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B|Maple syrup urine disease type 1A
★★☆☆2025→ Residue 1
NM_183050.4(BCKDHB):c.14dup (p.Ala6fs)Likely pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B
★★☆☆2025→ Residue 6
NM_183050.4(BCKDHB):c.1159C>T (p.Arg387Ter)Pathogenic
Maple syrup urine disease|BCKDHB-related disorder|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2025→ Residue 387
NM_183050.4(BCKDHB):c.583dup (p.Tyr195fs)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1A|Maple syrup urine disease type 1B
★★☆☆2025→ Residue 195
NM_183050.4(BCKDHB):c.612del (p.Phe204fs)Pathogenic
Maple syrup urine disease|Maple syrup urine disease type 1B
★★☆☆2025→ Residue 204
View on ClinVar ↗
Related Genes
ACADSBProtein interaction100%DLSTProtein interaction100%PDHA1Protein interaction100%OGDHProtein interaction100%DLATProtein interaction100%PDHXProtein interaction100%
Tissue Expression6 tissues
Liver
100%
Heart
64%
Brain
44%
Ovary
35%
Bone Marrow
22%
Lung
15%
Gene Interaction Network
Click a node to explore
BCKDHBACADSBDLSTPDHA1OGDHDLATPDHX
PROTEIN STRUCTURE
Preparing viewer…
PDB2BFD · 1.39 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.21LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.91 [0.69–1.21]
RankingsWhere BCKDHB stands among ~20K protein-coding genes
  • #6,309of 20,598
    Most Researched75
  • #290of 5,498
    Most Pathogenic Variants226 · top 10%
  • #12,682of 17,882
    Most Constrained (LOEUF)1.21
Genes detectedBCKDHB
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
PMID: 40009698
Sci Transl Med · 2025
1.00
2
GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.
PMID: 41487100
Circulation · 2026
0.90
3
Multi-omics insights into the pathogenesis of diabetic cardiomyopathy: epigenetic and metabolic profiles.
PMID: 39623870
Epigenomics · 2025
0.80
4
Neonatal maple syrup urine disease in China: two novel mutations in the BCKDHB gene and literature review.
PMID: 34187135
J Pediatr Endocrinol Metab · 2021
0.70
5
Successful treatment of severe MSUD in Bckdhb
PMID: 36880392
J Inherit Metab Dis · 2024
0.60